The Role of Elaborate in the Treatment of Patients With Brachin Mutations

The overall survival benefit that was seen was very clinically meaningful, with 67% of those in the elaborate arm alive at seven years versus approximately 45% in the CBO group. This data really showed a meaningful clinical benefit to patients with brachin mutation who were treated with elaborate. I think that it's really important for all of us to be thinking about how to apply this in clinical practice and find this subset of patients who gets the greatest benefit.